UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 500

Sortiert nach

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

Journal of viral hepatitis, 2010-01, Vol.17 (1), p.16-22

2010

Volltextzugriff (PDF)

Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

Journal of viral hepatitis, 2009-11, Vol.16 (11), p.784-789

2009

Volltextzugriff (PDF)

Reversing the Curse: Agricultural Millennialism at the Illinois Industrial University

Church history, 2004-12, Vol.73 (4), p.759-791

Smith, Brett H.

2004

Volltextzugriff (PDF)

[518] EFFICACY OF ENTECAVIR AND LAMIVUDINE IN CHRONIC HEPATITIS B PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS

Journal of hepatology, 2007, Vol.46, p.S197-S197

2007

Volltextzugriff (PDF)

20 ENTECAVIR MAINTAINS A HIGH GENETIC BARRIER TO HBV RESISTANCE THROUGH 6 YEARS IN NAIVE PATIENTS

Journal of hepatology, 2009, Vol.50, p.S10-S10

2009

Volltextzugriff (PDF)

Cellular Tropism and Viral Interleukin-6 Expression Distinguish Human Herpesvirus 8 Involvement in Kaposi’s Sarcoma, Primary Effusion Lymphoma, and Multicentric Castleman’s Disease

Journal of Virology, 1999-05, Vol.73 (5), p.4181-4187

1999

Volltextzugriff (PDF)

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy

AIDS (London), 2008-09, Vol.22 (14), p.1779-1787

2008

Volltextzugriff (PDF)

A Place Somewhat Apart: The Private Worlds of a Late Nineteenth-Century Public University - By Philip Harrold. Princeton Theological Monograph Series 63. Eugene, Ore.: Pickwick, 2006. xii + 243 pp. $26.00 paper

Church history, 2007-09, Vol.76 (3), p.661-662

Smith, Brett H.

2007

Volltextzugriff (PDF)

Effect of Stavudine on Human Immunodeficiency Virus Type 1 Virus Load as Measured by Quantitative Mononuclear Cell Culture, Plasma RNA, and Immune Complex-Dissociated Antigenemia

The Journal of infectious diseases, 1996-05, Vol.173 (5), p.1252-1255

1996

Volltextzugriff (PDF)

PMC39 USING MIXED TREATMENT COMPARISON MODELING TO COMPARE PROPORTIONS OF NAIVE HBEAG(+) CHB PATIENTS WHO ACHIEVED UNDETECTABLE HBV DNA

Value in health, 2009, Vol.12 (7), p.A394-A394

2009

Volltextzugriff (PDF)

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naÃ¯ve HBeAg-positive patients with chronic hepatitis B: Loss of HBsAg antigen with entecavir

Journal of viral hepatitis, 2010-01, Vol.17 (1), p.16-22

2010

Volltextzugriff (PDF)

P.086 Efficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis B

Journal of clinical virology, 2006, Vol.36, p.S87-S87

2006

Volltextzugriff (PDF)

Efficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis B

Journal of clinical virology, 2006-01, Vol.36, p.S87-S87

2006

Volltextzugriff (PDF)

513 Effects of entecavir and lamivudine on advanced liver fibrosis after 48 weeks of treatment in patients with CHB infection: Results of three pivotal trials

Journal of hepatology, 2006-04, Vol.44, p.S191-S191

2006

Volltextzugriff (PDF)

80 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

Journal of hepatology, 2006-04, Vol.44, p.S36-S36

2006

Volltextzugriff (PDF)

512 Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B

Journal of hepatology, 2006-04, Vol.44, p.S190-S191

2006

Volltextzugriff (PDF)

45 Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(−) chronic hepatitis B patients (study ETV-027)

Journal of hepatology, 2006-04, Vol.44, p.S21-S22

2006

Volltextzugriff (PDF)

P.090 Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)

Journal of clinical virology, 2006, Vol.36, p.S89-S89

2006

Volltextzugriff (PDF)

Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

Journal of clinical virology, 2006-01, Vol.36, p.S55-S55

2006

Volltextzugriff (PDF)

O.183 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

Journal of clinical virology, 2006, Vol.36, p.S55-S55

2006

Volltextzugriff (PDF)

P.082 Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)

Journal of clinical virology, 2006, Vol.36, p.S86-S86

2006

Volltextzugriff (PDF)

Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)

Journal of clinical virology, 2006-01, Vol.36, p.S86-S86

2006

Volltextzugriff (PDF)

Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)

Journal of clinical virology, 2006-01, Vol.36, p.S89-S89

2006

Volltextzugriff (PDF)

Cytomegalovirus as a Primary Pulmonary Pathogen in AIDS

Chest, 1997-01, Vol.111 (1), p.128-134

1997

Volltextzugriff (PDF)

A Place Somewhat Apart: The Private Worlds of a Late Nineteenth-Century Public University

Church History, 2007, Vol.76 (3), p.661-662

Smith, Brett H.

2007

Volltextzugriff (PDF)

1 – 25 von 500

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(459)
Mit Volltextzugriff
(421)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

Reversing the Curse: Agricultural Millennialism at the Illinois Industrial University

[518] EFFICACY OF ENTECAVIR AND LAMIVUDINE IN CHRONIC HEPATITIS B PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS

20 ENTECAVIR MAINTAINS A HIGH GENETIC BARRIER TO HBV RESISTANCE THROUGH 6 YEARS IN NAIVE PATIENTS

Cellular Tropism and Viral Interleukin-6 Expression Distinguish Human Herpesvirus 8 Involvement in Kaposi’s Sarcoma, Primary Effusion Lymphoma, and Multicentric Castleman’s Disease

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy

A Place Somewhat Apart: The Private Worlds of a Late Nineteenth-Century Public University - By Philip Harrold. Princeton Theological Monograph Series 63. Eugene, Ore.: Pickwick, 2006. xii + 243 pp. $26.00 paper

Effect of Stavudine on Human Immunodeficiency Virus Type 1 Virus Load as Measured by Quantitative Mononuclear Cell Culture, Plasma RNA, and Immune Complex-Dissociated Antigenemia

PMC39 USING MIXED TREATMENT COMPARISON MODELING TO COMPARE PROPORTIONS OF NAIVE HBEAG(+) CHB PATIENTS WHO ACHIEVED UNDETECTABLE HBV DNA

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naÃ¯ve HBeAg-positive patients with chronic hepatitis B: Loss of HBsAg antigen with entecavir

P.086 Efficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis B

Efficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis B

513 Effects of entecavir and lamivudine on advanced liver fibrosis after 48 weeks of treatment in patients with CHB infection: Results of three pivotal trials

80 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

512 Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B

45 Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(−) chronic hepatitis B patients (study ETV-027)

P.090 Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)

Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

O.183 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

P.082 Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)

Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)

Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)

Cytomegalovirus as a Primary Pulmonary Pathogen in AIDS

A Place Somewhat Apart: The Private Worlds of a Late Nineteenth-Century Public University

Suchergebnisse filtern